(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 November 2011 (10.11.2011)

PCT

(10) International Publication Number
WO 2011/138392 A1

(51) **International Patent Classification**:
C07K 16/28 (2006.01) ***C07K 16/46*** (2006.01)
A61K 39/395 (2006.01) ***C12N 15/113*** (2010.01)
A61P 35/00 (2006.01)

(21) **International Application Number**:
PCT/EP2011/057202

(22) **International Filing Date**:
5 May 2011 (05.05.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/331,985 6 May 2010 (06.05.2010) US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **CONG, Feng** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **ETTENBERG, Seth** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HARTLEPP, Felix** [DE/DE]; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **KLAGGE, Ingo** [DE/DE]; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE).

(74) **Agent**: **VON SPRECHER, Georg**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/138392 A1

(54) **Title**: COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN -RELATED PROTEIN 6 (LRP6) ANTIBODIES

(57) **Abstract**: The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof.